Literature DB >> 8258239

Soluble CD4, CD8 in patients with polymyositis/dermatomyositis.

Y Tokano1, T Obara, H Hashimoto, K Okumura, S Hirose.   

Abstract

The concentrations of soluble CD4 (sCD4) and soluble CD8 (sCD8) were determined in 64 patients with polymyositis/dermatomyositis (PM/MD). The patients with PM/DM had significantly higher concentrations of sCD8, though the concentrations of sCD4 did not significantly increase. Patients with high concentrations of sCD8 tended to have too high concentrations of soluble interleukin-2 receptor (sIL-2R). The patients with high levels of myogenic enzymes tended to have high concentrations of sCD8. The results of a serial study indicated that the concentrations of sCD8 decreased simultaneously with the decrease of the myogenic enzymes. These results may suggest that the activation of CD8+ cells are related to muscular involvement.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8258239     DOI： 10.1007/bf02231582

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  24 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.

Authors:  D Degiannis; J R Seibold; M Czarnecki; J Raskova; K Raska
Journal:  Arthritis Rheum       Date:  1990-03

3.  Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells.

Authors:  K Arahata; A G Engel
Journal:  Ann Neurol       Date:  1988-05       Impact factor: 10.422

4.  Detection of immune complexes in polymyositis.

Authors:  W M Behan; T Barkas; P O Behan
Journal:  Acta Neurol Scand       Date:  1982-04       Impact factor: 3.209

5.  HLA-DP-positive T cells in patients with systemic lupus erythematosus.

Authors:  Y Tokano; T Hishikawa; T Hirose; I Sekigawa; H Hashimoto; K Okumura; S Hirose
Journal:  Autoimmunity       Date:  1990       Impact factor: 2.815

6.  Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups.

Authors:  F W Miller; L A Love; S A Barbieri; J E Balow; P H Plotz
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation.

Authors:  D H Campen; D A Horwitz; F P Quismorio; G R Ehresmann; W J Martin
Journal:  Arthritis Rheum       Date:  1988-11

8.  Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.

Authors:  S Sawada; S Sugai; S Iijima; M Takei; E Paredes; T Hayama; S Nishinarita; Y Hosokawa; T Horie; T Obara
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Activated peripheral blood mononuclear cells detected by murine monoclonal antibodies to proliferating cell nuclear antigen in active lupus patients.

Authors:  A Murashima; Y Takasaki; M Ohgaki; H Hashimoto; T Shirai; S Hirose
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317
View more
  2 in total

1.  Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities.

Authors:  A Kuryliszyn-Moskal
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 2.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.